Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?

TheMotleyFool

0 0

Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?: https://g.foolcdn.com/editorial/images/768402/investors-evaluating-a-stock-purchase-getty.jpg

Shares of Novo Nordisk (NYSE: NVO) rose to a new all-time high on Thursday, March 7. The market was responding to encouraging results from a clinical trial with an experimental weight-management drug called amycretin.

Amycretin is an orally available treatment candidate, which could give it a big leg up if it eventually earns approval. Novo Nordisk's Wegovy and Eli Lilly's (NYSE: LLY) Zepbound are racking up billions in annual sales as weekly injectables.

Is Novo Nordisk a buy now? Let's look at the path ahead for amycretin to find out.

Source Fool.com

Like: 0

NVO

Share